ABBV's Newly Added Parkinson's Disease Drug Meets Second Study GoalZacks Investment Research • 09/27/24
AbbVie Submits Biologics License Application to the FDA for Telisotuzumab Vedotin (Teliso-V) in Previously Treated Non-Small Cell Lung CancerPRNewsWire • 09/27/24
AbbVie Announces Positive Topline Results from Phase 3 TEMPO-1 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's DiseasePRNewsWire • 09/26/24
New Analysis Demonstrates the Efficacy of RINVOQ® (upadacitinib) in Atopic Dermatitis with Varying Degrees of Severity in Head and Neck InvolvementPRNewsWire • 09/25/24
AbbVie Receives Positive CHMP Opinion for Mirvetuximab Soravtansine (ELAHERE®) for the Treatment of Certain Adult Ovarian CancerPRNewsWire • 09/20/24
2 Unstoppable S&P 500 Dividend Stocks to Buy Before They Beat the Market AgainThe Motley Fool • 09/19/24
Investing in Biotech or Pharma Stocks? Pay Attention to These 3 Things and You'll Win MoreThe Motley Fool • 09/14/24
Allergan Aesthetics Launches BOTOX® Cosmetic (onabotulinumtoxinA) for Masseter Muscle Prominence (MMP) in Adults in ChinaPRNewsWire • 09/11/24
UnitedHealth to remove AbbVie's Humira from some US drug reimbursement lists next yearReuters • 09/10/24
AbbVie Showcases Advancement of Solid Tumor Pipeline at ESMO 2024, with New Data in Tumor Types with High Unmet NeedsPRNewsWire • 09/09/24